The most recently approved GLP-1 receptor agonist, semaglutide 2.4 mg, has shown greater efficacy than the existing anti-obesity drugs and was recently approved for chronic weight management in adults with obesity [23]. This evidence concerns the gene GLP1R and Obesity.